We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Pushing the limits of targeted therapy in chronic myeloid leukaemia.
- Authors
O'Hare, Thomas; Zabriskie, Matthew S; Eiring, Anna M; Deininger, Michael W
- Abstract
Tyrosine kinase inhibitor (TKI) therapy targeting the BCR-ABL1 kinase is effective against chronic myeloid leukaemia (CML), but is not curative for most patients. Minimal residual disease (MRD) is thought to reside in TKI-insensitive leukaemia stem cells (LSCs) that are not fully addicted to BCR-ABL1. Recent conceptual advances in both CML biology and therapeutic intervention have increased the potential for the elimination of CML cells, including LSCs, through simultaneous inhibition of BCR-ABL1 and other newly identified, crucial targets.
- Publication
Nature reviews. Cancer, 2012, Vol 12, Issue 8, p513
- ISSN
1474-1768
- Publication type
Journal Article
- DOI
10.1038/nrc3317